Status:
COMPLETED
Different Effects of Non-calcium Phosphate Binders on Serum Calcium
Lead Sponsor:
Medical University of Lodz
Collaborating Sponsors:
Shire
Conditions:
Chronic Kidney Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Sevelamer hydrochloride (SE) can increase intestinal calcium absorption in contrast to lanthanum carbonate (LA). Study compared effect of LA and SE on serum and urine phosphate and calcium, and hormon...
Detailed Description
Recent experimental studies have shown that a non-calcium based phosphate binder sevelamer hydrochloride can increase intestinal calcium absorption in contrast to lanthanum carbonate. It is unknown wh...
Eligibility Criteria
Inclusion
- adult patient
- with eGFR ≤45 ml/min
Exclusion
- hypercalcemia (\>ULN),
- serum phosphate \>1.2 times normal value
- calcium-phosphate disturbances not associated with CKD, e.g. Paget disease, osteoporosis, any bone fracture within 6 months before study, multiple myeloma or any neoplastic disease, liver or biliary tract disease, primary hyperparathyroidism
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT03451019
Start Date
March 1 2018
End Date
December 30 2020
Last Update
July 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nephrology, Hypertension and Kidney Transplantation
Lodz, Poland, 90-153